Fresenius SE & Co. KGaA FRE

mAbxience today announced that Fresenius SE & Co. KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, building on the successful partnership established between the two companies in 2022 and marking the beginning of a new phase of growth for the company.

LAKE ZURICH, Ill., September 30, 2026--Fresenius Kabi, part of the global healthcare company Fresenius, was awarded the 2026 Pharmacy Strategic Programs Excellence Award by Vizient®, the nation’s largest provider-driven healthcare performance improvement company.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Waltz Health®, an EVERSANA® company developing technologies and services that support better-informed decisions on prescription care and Fresenius Kabi®, an operating company of Fresenius, and a leading provider of essential medicines and medical technologies, today announced an agreement to provide employers, payers and pharmacy benefit managers (PBMs) with direct access to three competitively priced biosimilars.

mAbxience, a majority-owned company of Fresenius SE & Co. KGaA (XETR: FRE) (OTCM: FSNUY) with partial ownership from Insud Pharma; and Sandoz (SIX: SDZ) (OTCQX: SDZNY), the global leader in affordable medicines, today announced a licensing, development, manufacturing and commercialization agreement for an emicizumab biosimilar candidate. The collaboration agreement combines mAbxience's proven development and manufacturing capabilities with Sandoz's global commercial reach, creating a pathway to

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Fresenius SE & Co. (FSNUY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Fresenius SE & Co KGaA (FSNUY) delivers robust first-half results, lifting core EPS growth outlook to 10%-15% as biopharma surges 38% and Helios maintains resilient margins.

BAD HOMBURG, Germany, August 03, 2026--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1

DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.

BAD HOMBURG, Germany, July 31, 2026--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to the reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration.

Fresenius SE KGaA has delivered a 65.9% return over the past three years, yet the stock still screens as undervalued on Simply Wall St's broader checks, which raises the question of how much of that progress the current €44.78 share price is already reflecting. Over the last three years Fresenius SE KGaA returned 65.9%, which puts recent gains front and center when judging whether the current price still offers value. Plans for a more than €200 million Fresenius Ventures fund can support...

Disposables lead the product segment, while plasmapheresis holds the largest procedure share. North America dominates the market. Key players include Terumo, Fresenius, Haemonetics, BD and B. Braun. Apheresis Market Apheresis Market Dublin, July 24, 2026 (GLOBE NEWSWIRE) -- The "Apheresis Market by Product, Procedure, Application, Technology, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global apheresis market is projected to grow from USD 3.02 bil

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to...